Literature DB >> 3733302

Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects.

K N Masihi, W Lange, W Brehmer, E Ribi.   

Abstract

The ability of nontoxic monophosphoryl lipid A (MPL) to stimulate nonspecific resistance against viral infection was investigated. Mice pretreated intravenously with squalane-in-water emulsions of MPL, alone or in combination with other immunostimulants, were given an aerosol of influenza virus three weeks after the pretreatment. Complete protection against lethal influenza virus infection was conferred when MPL was combined with trehalose dimycolate (TDM). The protective activity of MPL plus TDM combination was corroborated by a significant reduction of the lung virus titers. Combination of lower doses of MPL with TDM extracted from Mycobacterium bovis, but not with that of M. phlei, induced significant resistance to influenza virus. Preparations containing MPL alone, or combined with mycobacterial cell wall skeleton or muramyl dipeptide, were not effective. The adjuvant activity of MPL on bivalent influenza subunit vaccine was also studied. The primary antibody responses to influenza A and influenza B antigens were enhanced by the addition of MPL and were higher than the vaccine associated with aluminum hydroxide. The adjuvant activity of MPL was confirmed by the elevated secondary response. High levels of circulating antibodies were still present in the MPL group when antibody titers in the controls were waning.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3733302     DOI: 10.1016/0192-0561(86)90116-5

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  12 in total

1.  ESAT-6 subunit vaccination against Mycobacterium tuberculosis.

Authors:  L Brandt; M Elhay; I Rosenkrands; E B Lindblad; P Andersen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  The role of MyD88- and TRIF-dependent signaling in monophosphoryl lipid A-induced expansion and recruitment of innate immunocytes.

Authors:  Antonio Hernandez; Julia K Bohannon; Liming Luan; Benjamin A Fensterheim; Yin Guo; Naeem K Patil; Chase McAdams; Jingbin Wang; Edward R Sherwood
Journal:  J Leukoc Biol       Date:  2016-06-27       Impact factor: 4.962

Review 3.  Toll or toll-free adjuvant path toward the optimal vaccine development.

Authors:  Ken J Ishii; Shizuo Akira
Journal:  J Clin Immunol       Date:  2007-03-17       Impact factor: 8.317

4.  Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.

Authors:  Christopher W Cluff; Jory R Baldridge; Axel G Stöver; Jay T Evans; David A Johnson; Michael J Lacy; Valerie G Clawson; Vonnie M Yorgensen; Craig L Johnson; Mark T Livesay; Robert M Hershberg; David H Persing
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

5.  Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; L Q Tam; S P Chang; S E Case; C Hashiro; W A Siddiqui; T Shiba; S Kusumoto; S Kotani
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

Review 6.  Carbohydrate-based immune adjuvants.

Authors:  Nikolai Petrovsky; Peter D Cooper
Journal:  Expert Rev Vaccines       Date:  2011-04       Impact factor: 5.217

7.  Trehalose dimycolate enhances resistance to infection in neutropenic animals.

Authors:  G S Madonna; G D Ledney; T B Elliott; I Brook; J T Ulrich; K R Myers; M L Patchen; R I Walker
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

8.  Phosphorylated Hexa-Acyl Disaccharides Augment Host Resistance Against Common Nosocomial Pathogens.

Authors:  Antonio Hernandez; Liming Luan; Cody L Stothers; Naeem K Patil; Jessica B Fults; Benjamin A Fensterheim; Yin Guo; Jingbin Wang; Edward R Sherwood; Julia K Bohannon
Journal:  Crit Care Med       Date:  2019-11       Impact factor: 7.598

9.  Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.

Authors:  Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Paul M Sondel; Alexander L Rakhmilevich
Journal:  J Immunother       Date:  2013-01       Impact factor: 4.456

10.  Adjuvants for Leishmania vaccines: from models to clinical application.

Authors:  Vanitha S Raman; Malcolm S Duthie; Christopher B Fox; Greg Matlashewski; Steven G Reed
Journal:  Front Immunol       Date:  2012-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.